CoChat

Mesenchymal stem cells secretome: current trends and future challenges

Open access
Teixeira, FábioG, Salgado, AntónioJ · 2020 · Neural Regeneration Research
Cited by 125

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Mesenchymal stem cells (MSCs) secretome: a good candidate for medical biotechnology? Medical biotechnology is currently defined as the application of biotechnological tools for producing multiple technologies and products to health care, becoming an important bridge between different fields, namely neuroscience, regenerative medicine, pharmacology and bio-engineering (Pham, 2018). The use and manipulation of stem cells can potentially represent a medical biotechnology breakthrough that brings regenerative medicine to a new era. Actually, over the last decade, the use of stem cells has remarkably been proposed as a regenerative tool, and within it, MSCs have emerged as a promising therapeutic option. As a consequence, they currently represent an effective tool in the treatment of several diseases due to their tissue protective and reparative mechanisms (Phelps et al., 2018). Indeed, MSCs are the most frequently stem cell population used in clinical trials (as of the end of 2018, a total of 861 trials were registered according to the US National Institute of Health – https://clinicaltrials.gov), presenting key advantages such as (1) be isolated from a patient and used for autologous transplantation; (2) not divide uncontrollably and form teratomas; and (3) have the capability to differentiate into multiple lineages (Kusuma et al., 2017). The initial therapeutic rationale of the use of MSCs in regenerative medicine as mostly attributed to their capability of homing to injury sites and differentiates into different cell types, leading to tissue repair. Although promising, this theory was revisited at the beginning of the 20th century when, for the first time, Gnecchi and colleagues revealed that MSCs mediated its therapeutical effects by the secretion and release of trophic molecules, nowadays known as secretome (Gnecchi et al., 2005). Indeed, cell tracking analysis has revealed that when transplanted, MSCs (and stem cells in general) do not commonly become a part of the injured site, whereby accumulating pieces of evidence indicate that the secretome is considered the primary attribute of MSC-mediated repair and regeneration (Teixeira et al., 2013). MSC’s secretome has been described as a complex mixture of soluble products composed by a proteic soluble fraction (constituted by growth factors and cytokines), and a vesicular fraction composed by microvesicles and exosomes, which are involved in the transference of proteins and genetic material (e.g., microRNAs) to other cells, with promising therapeutic effects (Teixeira et al., 2013). Notably, MSCs secretome itself is starting to be considered a potential active pharmaceutical component, in which its vesicular portion has been revealing promising characteristics to be used as drug delivery system, mainly due to its homing capabilities, thereby opening an opportune window to specific and targeted compounds (drugs, proteins, etc.) release into damaged lesions (Bari et al., 2018) (Figure 1).Figure 1: MSCs secretome overview.A convergence in the scientific community is being formed on the close relation between MSCs therapeutic potential and their secretome. Indeed, pre-clinical studies using in vitro and in vivo models of disease have demonstrated promising results, with MSCs’ secretome potentiating cell proliferation, survival, and differentiation, as well as physiological/motor performance. Actually, it has been based on such results that points of discussion are being established regarding the development of guidelines to secretome production. Due to its highly dynamic profile, MSCs may be “educated/modulated” to produce the best secretome “cocktail” possible, according to the desired therapeutic goals. Although the efficacy of MSCs secretome has been notably established in numerous pre-clinical models, the development of a large-scale GMP secretome-based product is required, thereby representing a crucial step to make MSCs secretome closer to the widens the gap that has been existing for decades between MSCs experimental research and its clinical use. 3D: 3-Dimensions; AD: Alzheimer’s disease; GMP: good manufacturing protocol; Iv: intravenous injection; MSC: mesenchymal stem cell; PD: Parkinson’s disease; TBi: traumatic brain injury.The current view using cell transplantation-free strategies such as the one proposed by MSC’s secretome provides key advantages over (stem) cells transplantation. First, the secretome strategy overcomes the cells survival upon transplantation; second, secretome compounds have lower cell surface proteins expression, providing less immunogenicity when compared to living and proliferative cells (Vizoso et al., 2017); third, using the secretome as a ready-to-use product remarkably reduce the significant high number of cells needed for transplantation (7 × 106 cells/kg), as well as possible phenotypic and therapeutic potential alterations due to long periods of expansion of MSCs in vitro prior to transplantation; fourth, higher rates o

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/1673-5374.264455

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 125

Metadata

Authors
Teixeira, F., & Salgado, A.
Venue
Neural Regeneration Research
Publisher
Medknow
Published
2020
Volume
15
Issue
1
Pages
75
ISSN
1673-5374 (ISSN-L)
OpenAlex
W2974177428
Cited by
125
References
2
FWCI
6.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal stem cells secretome: current trends and future challenges. https://app.cochat.ai/papers/10.4103/1673-5374.264455
The paper
Teixeira, F., & Salgado, A. (2020). Mesenchymal stem cells secretome: current trends and future challenges. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.264455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.